Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;31(1):87-94.
doi: 10.1007/s40620-017-0396-8. Epub 2017 Apr 6.

Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study

Laura Girardat-Rotar  1 , Milo A Puhan  2 , Julia Braun  2 , Andreas L Serra  2   3
Affiliations

Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study

Laura Girardat-Rotar et al. J Nephrol. 2018 Feb.

Abstract

Background: Previous in vitro experiments of human polycystic kidney disease (PKD) cells reported that caffeine is a risk factor for the promotion of cyst enlargement in patients with autosomal dominant PKD (ADPKD). The relentless progression of ADPKD inclines the majority of physicians to advocate minimization of caffeine consumption despite the absence of clinical data supporting such a recommendation so far. This is the first clinical study to assess prospectively the association between coffee consumption and disease progression in a longitudinal ADPKD cohort.

Methods: Information on coffee consumption and disease progression was collected at each follow-up visit using standardized measurement methods. The main model for the outcomes, kidney size (height-adjusted total kidney volume, htTKV) and kidney function (estimated glomerular filtration rate, eGFR), was a linear mixed model. Patients entered the on-going Swiss ADPKD study between 2006 and June 2014 and had at least 1 visit every year. The sample size of the study population was 151 with a median follow-up of 4 visits per patient and a median follow-up time of 4.38 years.

Results: After multivariate adjustment for age, smoking, hypertension, sex, body mass index and an interaction term (coffee*visit), coffee drinkers did not have a statistically significantly different kidney size compared to non-coffee drinkers (difference of -33.03 cm3 height adjusted TKV, 95% confidence interval (CI) from -72.41 to 6.34, p = 0.10). After the same adjustment, there was no statistically significant difference in eGFR between coffee and non-coffee drinkers (2.03 ml/min/1.73 m2, 95% CI from -0.31 to 4.31, p = 0.089).

Conclusion: Data derived from our prospective longitudinal study do not confirm that drinking coffee is a risk factor for ADPKD progression.

Keywords: ADPKD; Coffee; Epidemiology; Kidney volume; Progression; Renal function decline.

PubMed Disclaimer

Conflict of interest statement

Funding

Laura Girardat-Rotar and Andreas L. Serra received a grant from the Marie Curie Project (TranCYST FP7-PEOPLE-MCA-ITN No. 317246).

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Zurich) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Figures

Fig. 1
Fig. 1
Adjusted prediction of kidney size (height adjusted total kidney volume, htTKV) with 95% confidence interval (CI), by coffee consumption group
Fig. 2
Fig. 2
Adjusted prediction of kidney function (estimated glomerular filtration rate, eGFR) with 95% CI, by coffee consumption group
See this image and copyright information in PMC

References

    1. Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ. The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2002;13(11):2723–2729. doi: 10.1097/01.ASN.0000025282.48298.7B. - DOI - PubMed
    1. Ars E, Bernis C, Fraga G, Martinez V, Martins J, Ortiz A, Rodriguez-Perez JC, Sans L, Torra R, Spanish Working Group on Inherited Kidney D Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014;29(Suppl 4):iv95–i105. doi: 10.1093/ndt/gfu186. - DOI - PubMed
    1. Torres VE. Therapies to slow polycystic kidney disease. Nephron Exp Nephrol. 2004;98(1):e1–e7. doi: 10.1159/000079926. - DOI - PubMed
    1. Devuyst O, Torres VE. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease. Curr Opin Nephrol Hypertens. 2013;22(4):459–470. doi: 10.1097/MNH.0b013e3283621510. - DOI - PubMed
    1. Vendramini LC, Nishiura JL, Baxmann AC, Heilberg IP. Caffeine intake by patients with autosomal dominant polycystic kidney disease. Braz J Med Biol Res. 2012;45(9):834–840. doi: 10.1590/S0100-879X2012007500120. - DOI - PMC - PubMed

Publication types

MeSH terms